Chemistry:Bucindolol
From HandWiki
Revision as of 13:24, 17 July 2022 by imported>Wincert (fixing)
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H25N3O2 |
| Molar mass | 363.461 g·mol−1 |
| 3D model (JSmol) | |
| |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]
See also
References
- ↑ 1.0 1.1 "formularyjournal.modernmedicine.com". http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bucindolol-A-beta-blocker-for-the-treatment-of-hea/ArticleStandard/Article/detail/601855.
- ↑ "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology 56 (1): 30–6. January 1998. doi:10.1159/000028179. PMID 9467185. http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=pha56030.
- ↑ "FDA rejects bucindolol and questions trial integrity « CardioBrief". 2 June 2009. http://cardiobrief.org/2009/06/02/fda-rejects-bucindolol-and-questions-trial-integrity/.
 |  |
